PD-0970 Biodistribution Data of ImmunoPET: A Phase 0/1 Study Characterising PD-L1 with 89Zr- Durvalumab

F. Hegi-Johnson,S. Rudd,P. Roselt, C. Wichmann, J. Callahan,T. Akhurst,P. Jackson, R. Hicks, A. Scott, P. Donnelly, T. John, G. Hanna, M. MacManus

Radiotherapy and Oncology（2023）

Cited 0|Views3

No score

Key words

durvalumab,immunopet

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined